SCHEMBL8310339

SCHEMBL8310339

CC(C)C(=O)NCc1cc(F)cc(F)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.56
ERCC4 Q92889 1/20 0.56
SMO Q99835 1/20 0.47
HPGD P15428 1/20 0.44
METAP2 P50579 2/20 0.43
PSEN1 P49768 5/20 0.43
PSEN2 P49810 5/20 0.43
APH1B Q8WW43 5/20 0.43
NCSTN Q92542 5/20 0.43
APH1A Q96BI3 5/20 0.43
PSENEN Q9NZ42 5/20 0.43
GAA P10253 1/20 0.42
ANPEP P15144 1/20 0.42
CYP3A4 P08684 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41
AURKA O14965 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18251695 0.90 ERCC1 (0.50) ERCC1ERCC4SMOHPGDPSEN1
SCHEMBL1562512 0.84 KMT2A (0.46) ERCC1ERCC4HPGDMETAP2PSEN1
Hydrochloric Acid SCHEMBL5967221 0.84 CARM1 (0.54) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL13103587 0.84 ERCC1 (0.54) ERCC1ERCC4SMOHPGD
SCHEMBL1379640 0.83 PSEN1 (0.45) ERCC1ERCC4HPGDMETAP2PSEN1
SCHEMBL13797510 0.83 ANPEP (0.60) ERCC1ERCC4SMOANPEPALDH1A1
SCHEMBL5017857 0.82 MAPK1 (0.43) ERCC1ERCC4HPGDMETAP2PSEN1
SCHEMBL12375175 0.81 HPGD (0.65) ERCC1ERCC4SMOHPGDGAA
SCHEMBL5017863 0.80 PDE10A (0.40) METAP2PSEN1PSEN2APH1BNCSTN
SCHEMBL20428059 0.79 ERCC1 (0.57) ERCC1ERCC4SMOGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656962-B2 Ring-contracted morphinans and the use thereof PURDUE PHARMA L.P. (US) 2017-05-23 US disclosed
US-7910609-B2 Inhibitors of integrin alpha2beta1 with modified urea moiety THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2011-03-22 US disclosed
US-20100267706-A1 Compounds, Compositions and Methods Comprising Pyridazine Derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-10-21 US disclosed
US-20100267706-A1 Compounds, Compositions and Methods Comprising Pyridazine Derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-10-21 US disclosed
US-20090197861-A1 INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-08-06 US disclosed
US-7217794-B2 Compounds and methods for treatment of thrombosis DAIAMED, INC. (US) 2007-05-15 US disclosed
US-7217794-B2 Compounds and methods for treatment of thrombosis DAIAMED, INC. (US) 2007-05-15 US disclosed
WO-2004089297-A2 COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES, LLC (US) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267706-A1 Compounds, Compositions and Methods Comprising Pyridazine Derivatives CFTR, PKD1, PKD2 ERCC1 3169/4885ERCC4 3540/4885SMO 669/4885
US-20090197861-A1 INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY ITGA2B, ITGA2, ITGB2 ERCC1 1996/4885ERCC4 2995/4885SMO 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.